· Published by Health Canada · Official notice
This is duplicated text of a letter from GlaxoSmithKline Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
November 1, 2007
Dear Health Care Professional:
Subject: New restrictions on the use of rosiglitazone products due to cardiac safety concerns (AVANDIAFootnote ®, AVANDAMETFootnote ® and AVANDARYLFootnote ™)
GlaxoSmithKline Inc., in consultation with Health Canada, would like to inform you of important new restrictions on the treatment of type 2 diabetes mellitus with the rosiglitazone-containing products: AVANDIAFootnote ® (rosiglitazone), AVANDAMET® (rosiglitazone and metformin), and AVANDARYLFootnote ™ (rosiglitazone and glimepiride).
Further to a Health Canada assessment of adverse event reports, published articlesFootnote * and other available information on congestive heart failure, myocardial infarction, and related events, the Canadian Product Monographs for rosiglitazone-containing products are being updated and will include the following new usage restrictions:
Also, as a reminder:
Dual therapy
When adequate glycemic control is not obtained through diet and exercise plus monotherapy, then rosiglitazone can be used in dual therapy, as follows:
Rosiglitazone can be added to (not substituted for) the monotherapy agent.
Other new information in the Product Monographs will include clinical trial evidence regarding cardiac ischemic events associated with rosiglitazone.
Patients are being advised to talk to their doctors about the risks of continuing rosiglitazone therapy if they have underlying heart disease, or are at high risk of heart attack or heart failure (see the Public Communication associated with this Letter).
As soon as they are available, the revised Product Monographs for AVANDIA®, AVANDAMETFootnote ® and AVANDARYLFootnote ™ will replace the versions dated July 2007 (AVANDAMETFootnote ® and AVANDARYLFootnote ™ ) and October 2007 (AVANDIA®) that are posted at www.gsk.ca.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. As always, any serious or unexpected adverse reactions in patients receiving AVANDIAFootnote ®, AVANDAMETFootnote ® and AVANDARYL™ should be reported to GlaxoSmithKline or Health Canada at the following addresses:
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Tel.: 1-800-387-7374
www.gsk.ca
Any suspected adverse reaction can also be reported to:
Canada Vigilance Program
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: 613-957-0337 or Fax: 613-957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866-234-2345
Fax: 866-678-6789
CanadaVigilance@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC@hc-sc.gc.ca
Tel: 613-954-6522
Fax: 613-952-7738
Your professional commitment in this regard has an important role in protecting the well-being of your patients by contributing to early signal detection and informed drug use.
Any questions from health care professionals may be directed to our Medical Information department via GSK Customer Service at 1-800-387-7374.
Sincerely,
original signed by
Dr. Tjark Reblin, MD, MBA
Vice President, Medical Division and Chief Medical Officer
GlaxoSmithKline Inc.
Recent publications include:
Avandia® and Avandamet® are registered trademarks, used under license by GlaxoSmithKline Inc.
Avandaryl™ is a trademark, used under license by GlaxoSmithKline Inc.